| Project/Area Number |
15K09068
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
佐藤 光希 新潟大学, 医歯学総合病院, 助教 (40600044)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SUDA Masayoshi 新潟大学, 医歯学総合病院, 医員 (70714509)
|
|---|
| Research Collaborator |
FUSE Ichiro
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 抗凝固療法 / 直接型経口抗凝固薬 / ワルファリン / DOAC / 生理的凝固阻止因子 / NOAC / 血管内皮結合型組織因子経 路インヒビター / プロトロンビンフラグメント1+2 / 血管内皮結合型組織因子経路インヒビター |
|---|
| Outline of Final Research Achievements |
The major findings of the present study were as follows: (1) direct oral anticoagulants (DOACs) effectively decreased thrombin generation at both the trough and peak concentration times, although the reduction of thrombin generation by DOACs was smaller than that achieved by warfarin treatment in the therapeutic range. (2) Patients on DOAC treatment showed a greater increase of thrombin generation after vascular injury than patients on warfarin treatment. (3) DOAC treatment had a more favorable effect on physiological coagulation inhibitors than warfarin treatment. These results suggest that, in contrast to warfarin treatment, DOAC treatment preserves thrombin generation in response to vascular injury and maintains protein C, protein S, and factor VII levels, which could partly explain the lower risk of hemorrhagic complications and thromboembolic events in patients using these anticoagulants.
|
